MF59 adjuvant: the best insurance against influenza strain diversity

The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells

(2014) A. Seubert et al.   JOURNAL OF IMMUNOLOGY

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes

(2011) Samuele Calabro et al.   VACCINE

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children

(2010) Yuji Yasuda et al.   ADVANCES IN THERAPY

A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly

(2010) E. Fragapane et al.   Clinical and Vaccine Immunology

Recipients of Vaccine against the 1976 “Swine Flu” Have Enhanced Neutralization Responses to the 2009 Novel H1N1 Influenza Virus

(2010) Jonathan A. McCullers et al.   CLINICAL INFECTIOUS DISEASES

Monitoring Adverse Events of the Vaccination Campaign Against Influenza A (H1N1) in the Netherlands

(2010) Eugène P. van Puijenbroek et al.   DRUG SAFETY

Prior infection with classical swine H1N1 influenza viruses is associated with protective immunity to the 2009 pandemic H1N1 virus

(2010) John C. Kash et al.   Influenza and Other Respiratory Viruses

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

(2010) Davide Corti et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunity to Pre-1950 H1N1 Influenza Viruses Confers Cross-Protection against the Pandemic Swine-Origin 2009 A (H1N1) Influenza Virus

(2010) I. Skountzou et al.   JOURNAL OF IMMUNOLOGY

Multiple Infections with Seasonal Influenza A Virus Induce Cross‐Protective Immunity against A(H1N1) Pandemic Influenza Virus in a Ferret Model

(2010) Karen L. Laurie et al.   JOURNAL OF INFECTIOUS DISEASES

Research and development of universal influenza vaccines

(2010) Lanying Du et al.   MICROBES AND INFECTION

Vaccinate before the next pandemic?

(2010) Klaus Stöhr   NATURE

Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence

(2010) T. Vesikari et al.   PEDIATRICS

Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development

(2010) M. F. Ducatez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccines with MF59 Adjuvant Expand the Antibody Repertoire to Target Protective Sites of Pandemic Avian H5N1 Influenza Virus

(2010) S. Khurana et al.   Science Translational Medicine

Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009–2010 and comparison with previous estimates and global action plan targets

(2010) Jeffrey Partridge et al.   VACCINE

Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates

(2010) Filippo Ansaldi et al.   VACCINE

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis

(2010) Steven Black et al.   VACCINE

Immunogenicity, Safety, and Cross‐Reactivity of an Inactivated, Adjuvanted, Prototype Pandemic Influenza (H5N1) Vaccine: A Phase II, Double‐Blind, Randomized Trial

(2009) Jiang Wu et al.   CLINICAL INFECTIOUS DISEASES

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data

(2009) Geert Leroux-Roels   EXPERT OPINION ON BIOLOGICAL THERAPY

A Cell Culture (Vero)–Derived H5N1 Whole‐Virus Vaccine Induces Cross‐Reactive Memory Responses

(2009) Hartmut J. Ehrlich et al.   JOURNAL OF INFECTIOUS DISEASES

Universal epitopes of influenza virus hemagglutinins?

(2009) Taia T Wang et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

(2009) Jianhua Sui et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Response to a Monovalent 2009 Influenza A (H1N1) Vaccine

(2009) Michael E. Greenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine

(2009) Tristan W. Clark et al.   NEW ENGLAND JOURNAL OF MEDICINE

Responses to 2009 H1N1 Vaccine in Children 3 to 17 Years of Age

(2009) Adriano Arguedas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults

(2009) Angelika Banzhoff et al.   PLoS One

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

(2009) G. Galli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody Recognition of a Highly Conserved Influenza Virus Epitope

(2009) D. C. Ekiert et al.   SCIENCE

Seasonal Influenza Vaccine Provides Priming for A/H1N1 Immunization

(2009) G. Del Giudice et al.   Science Translational Medicine

Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses

(2009) Isabella Alberini et al.   VACCINE

Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness

(2009) Christopher J. Phillips et al.   VACCINE

Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets

(2009) Heather L. Forrest et al.   VACCINE

Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults

(2009) Daniel Wai-Sing Chu et al.   VACCINE

Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection

(2009) Filippo Ansaldi et al.   VACCINE

MF59®-adjuvanted influenza vaccine (FLUAD®) in children: Safety and immunogenicity following a second year seasonal vaccination

(2009) T. Vesikari et al.   VACCINE

Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages

(2009) B. Camilloni et al.   VACCINE

MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database

(2009) Michele Pellegrini et al.   VACCINE

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial

(2009) Wendy Keitel et al.   VACCINE

Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study

(2009) Isabel Leroux-Roels et al.   VACCINE

Exposure to MF59-adjuvanted influenza vaccines during pregnancy—A retrospective analysis

(2009) Theodore Tsai et al.   VACCINE

Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets

(2009) Surender Khurana et al.   PLOS MEDICINE

Seasonal and Pandemic Influenza: A 2007 Update on Challenges and Solutions

(2008) Arnold S. Monto et al.   CLINICAL INFECTIOUS DISEASES

An Adjuvanted, Low‐Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross‐Reactive Immune Responses in Healthy Adults

(2008) Karin Levie et al.   JOURNAL OF INFECTIOUS DISEASES

Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults

(2008) David I. Bernstein et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation of the Safety and Immunogenicity of a Booster (Third) Dose of Inactivated Subvirion H5N1 Influenza Vaccine in Humans

(2008) Kenneth M. Zangwill et al.   JOURNAL OF INFECTIOUS DISEASES

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

(2008) Lance C Jennings et al.   LANCET INFECTIOUS DISEASES

Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1

(2008) Iain Stephenson et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture

(2008) Hartmut J. Ehrlich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Broad Clade 2 Cross-Reactive Immunity Induced by an Adjuvanted Clade 1 rH5N1 Pandemic Influenza Vaccine

(2008) Isabel Leroux-Roels et al.   PLoS One

Cross-Protection against Lethal H5N1 Challenge in Ferrets with an Adjuvanted Pandemic Influenza Vaccine

(2008) Benoît Baras et al.   PLoS One

Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells

(2008) Mark Throsby et al.   PLoS One

Molecular and cellular signatures of human vaccine adjuvants

(2008) F. Mosca et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice

(2008) Andreas Wack et al.   VACCINE

Safety of MF59™ adjuvant

(2008) Viola Schultze et al.   VACCINE

Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

(2008) Filippo Ansaldi et al.   VACCINE